A heterobifunctional IRAK4-targeting degrader impairs myddosome signaling in acute kidney injury and ameliorates kidney fibrosis. (PubMed, Commun Biol) - May 25, 2026 - "In vivo, KTX-545 showed increased efficacy compared to the small molecule IRAK4 kinase inhibitor CA-4948 in ameliorating fibrosis following ischemia/reperfusion injury. Collectively, our results indicate that targeted degradation of IRAK4 is a new promising therapeutic approach for the treatment of renal fibrosing disorders."
Journal • Acute Kidney Injury • Cardiovascular • Fibrosis • Immunology • Nephrology • Renal Disease • Reperfusion Injury • Targeted Protein Degradation • IRAK4
|
|
Andres Ebergenyi-Camarena; Anthony Slavin; Antonio Esquivel-Herrera; Dario Ruben Lemos; Diana Ofelia Lopez-Cantu; Jocelynn Colunga-Minutti; Leonardo Gael Pelayo-Minero; Marta Lopez-Marfil; Matthew Weiss; Nello Mainolfi; Veronica Campbell; Xiaozhang Zheng; Xichi Wang
|